Treatment with ddAVP improves platelet-based coagulation in a rat model of traumatic hemorrhagic shock

Objectives Trauma-induced hemorrhagic shock is characterized by increased endothelial permeability and coagulopathy. Vasopressin analog ddAVP (desmopressin) acts by reorganizing and redistributing adhesive and tight junction molecules, enhancing endothelial barrier function. Furthermore, ddAVP increases von Willebrand factor (vWF) plasma levels and thereby potentially enhances platelet-based coagulation. The objective of this study was to assess whether the use of ddAVP results in improvement of both endothelial barrier function and platelet-based coagulation, thereby improving shock reversal and reduce organ failure in a rat model of trauma and transfusion. Methods Blood products were prepared from syngeneic rat blood according to blood bank standards. Polytrauma was induced in Sprague Dawley rats by a fractured femur and crush injury to the intestines and liver. The rats were hemorrhaged until a mean arterial pressure of 40 mm Hg and transfused with RBCs, fresh frozen plasmas and platelets in a 1:1:1 ratio, and randomized to receive a single dose of ddAVP (n=7 per group). Blood samples were taken up to 6 hours after trauma to assess biochemistry, markers of endothelial injury and coagulation status by rotational thromboelastometry (ROTEM). Organ damage was assessed by histopathology. Results Rats receiving ddAVP showed significantly better shock reversal compared with controls. Also, coagulation parameters remained stable in the ddAVP treated group, whereas rats in the control group showed deterioration of coagulation parameters, including decreased clot strength and decreased platelet functioning (89% (IQR 82% to 92%) of baseline values). Platelet count and vWF antigen levels at exsanguination did not differ between groups. ddAVP did not reduce markers of endothelial dysfunction nor markers of organ injury. Conclusions The use of ddAVP in a rat trauma-transfusion model improved shock parameters and ROTEM parameters of clot formation. However, this did not abrogate the amount of organ failure. Level of evidence Level III.

[1]  B. Abella,et al.  Effect of Low-Dose Supplementation of Arginine Vasopressin on Need for Blood Product Transfusions in Patients With Trauma and Hemorrhagic Shock: A Randomized Clinical Trial. , 2019, JAMA surgery.

[2]  P. Spinella,et al.  Washing or filtering of blood products does not improve outcome in a rat model of trauma and multiple transfusion , 2018, Transfusion.

[3]  Carlos V. R. Brown,et al.  Desmopressin Is A Transfusion Sparing Option To Reverse Platelet Dysfunction In Patients With Severe Traumatic Brain Injury. , 2019, The journal of trauma and acute care surgery.

[4]  M. Cohen,et al.  Perhaps it's not the platelet: Ristocetin uncovers the potential role of von Willebrand factor in impaired platelet aggregation following traumatic brain injury , 2018, The journal of trauma and acute care surgery.

[5]  S. Stern,et al.  Damage Control Resuscitation Supplemented with Vasopressin in a Severe Polytrauma Model with Traumatic Brain Injury and Uncontrolled Internal Hemorrhage. , 2018, Military medicine.

[6]  G. Wanner,et al.  Hemorrhagic shock drives glycocalyx, barrier and organ dysfunction early after polytrauma , 2018, Journal of critical care.

[7]  S. Cimbanassi,et al.  Evaluation of capillary leakage after vasopressin resuscitation in a hemorrhagic shock model , 2018, World Journal of Emergency Surgery.

[8]  J. Lord,et al.  Endotheliopathy of Trauma is an on-Scene Phenomenon, and is Associated with Multiple Organ Dysfunction Syndrome: A Prospective Observational Study , 2017, Shock.

[9]  C. Wade,et al.  Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma. , 2017, Journal of the American College of Surgeons.

[10]  M. Trivella,et al.  Desmopressin use for minimising perioperative blood transfusion. , 2017, The Cochrane database of systematic reviews.

[11]  C. Wade,et al.  Sympathoadrenal activation and endotheliopathy are drivers of hypocoagulability and hyperfibrinolysis in trauma: A prospective observational study of 404 severely injured patients , 2017, The journal of trauma and acute care surgery.

[12]  G. Landoni,et al.  Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta‐analysis of randomized controlled trials , 2017, Journal of thrombosis and haemostasis : JTH.

[13]  C. Wade,et al.  Traumatic Endotheliopathy: A Prospective Observational Study of 424 Severely Injured Patients , 2016, Annals of surgery.

[14]  G. Dobson,et al.  Differential contributions of platelets and fibrinogen to early coagulopathy in a rat model of hemorrhagic shock. , 2016, Thrombosis research.

[15]  D. Granger,et al.  Blood cells and endothelial barrier function , 2015, Tissue barriers.

[16]  Jun Sun,et al.  Pulmonary Permeability Assessed by Fluorescent-Labeled Dextran Instilled Intranasally into Mice with LPS-Induced Acute Lung Injury , 2014, PloS one.

[17]  Juanjuan Fan,et al.  The Selective Vasopressin Type 1a Receptor Agonist Selepressin (FE 202158) Blocks Vascular Leak in Ovine Severe Sepsis* , 2014, Critical care medicine.

[18]  R. Montgomery,et al.  Evaluation of von Willebrand Factor and von Willebrand Factor Propeptide in Models of Vascular Endothelial Cell Activation, Perturbation, and/or Injury , 2014, Toxicologic pathology.

[19]  R. Hahn,et al.  Effects of different fluid regimes and desmopressin on uncontrolled hemorrhage during hypothermia in the rat. , 2012, Therapeutic hypothermia and temperature management.

[20]  J. Low,et al.  Vasopressin and its role in critical care , 2008 .

[21]  J. Djurhuus,et al.  Pharmacokinetics and pharmacodynamics of desmopressin administered orally versus intravenously at daytime versus night-time in healthy men aged 55–70 years , 2004, European Journal of Clinical Pharmacology.

[22]  J. Schumacher,et al.  Organ-Specific Extravasation of Albumin-Bound Evans Blue During Nonresuscitated Hemorrhagic Shock in Rats , 2003, Shock.

[23]  J. Kaufmann,et al.  Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP) , 2003, Journal of thrombosis and haemostasis : JTH.

[24]  Vischer Um,et al.  Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. , 1997 .